Long-term vitamin E supplementation fails to reduce lipid peroxidation in people at cardiovascular risk: analysis of underlying factors

被引:8
作者
Chiabrando, C
Avanzini, F
Rivalta, C
Colombo, F
Fanelli, R
Palumbo, G
Roncaglioni, MC
机构
[1] Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, I-20157 Milan, Italy
[2] Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, I-20157 Milan, Italy
[3] Azienda Osped Osped San Carlo Borromeo, Div Med V Piano, I-20153 Milan, Italy
来源
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE | 2002年 / 3卷 / 1期
关键词
vitamin E; cardiovascular prevention; lipid peroxidation; F2-isoprostane; hypertension;
D O I
10.1186/1468-6708-3-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Antioxidant supplementation with vitamin E had no effect in the prevention of cardiovascular diseases (CVD) in three recent large, randomized clinical trials. In order to reassess critically the role of vitamin E in CVD prevention, it is important to establish whether these results are related to a lack of antioxidant action. Methods: We examined the in vivo antioxidant effect of vitamin E (300 mg/day for about three years) in 144 participants in the Primary Prevention Project (females and males, aged greater than or equal to 50 y, with at least one major CV risk factor, but no history of CVD). Urinary 8-epi-PGF(2alpha) (isoprostane F-2alpha-III or 15-F-2t-isoP), a validated biomarker of lipid peroxidation, was measured by mass spectrometry. Results: Urinary excretion of 8-epi-PGF(2alpha) [pg/mg creatinine, median ( range)] was 141 (67-498) in treated and 148 (76-561) in untreated subjects (p = 0.10). Taking into account possible confounding variables, multiple regression analysis confirmed that vitamin E had no significant effect on this biomarker. Levels of 8-epi-PGF(2alpha) were in the normal range for most subjects, except smokers and those with uncontrolled blood pressure or hyperglycemia. Conclusions: Prolonged vitamin E supplementation did not reduce lipid peroxidation in subjects with major cardiovascular risk factors. The observation that the rate of lipid peroxidation was near normal in a large proportion of subjects may help explain why vitamin E was not effective as an antioxidant in the PPP study and was ineffective for CVD prevention in large scale trials.
引用
收藏
页数:7
相关论文
共 37 条
  • [1] AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS
    ANDERSON, KM
    WILSON, PWF
    ODELL, PM
    KANNEL, WB
    [J]. CIRCULATION, 1991, 83 (01) : 356 - 362
  • [2] Measurement of urinary 8-epi-prostaglandin F-2 alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction gas chromatography mass spectrometry. Basal levels in smokers and nonsmokers
    Bachi, A
    Zuccato, E
    Baraldi, M
    Fanelli, R
    Chiabrando, C
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1996, 20 (04) : 619 - 624
  • [3] Oxidative stress and vascular damage in hypertension
    Berry, C
    Brosnan, MJ
    Fennell, J
    Hamilton, CA
    Dominiczak, AF
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (02) : 247 - 255
  • [4] In vivo lipid peroxidation and platelet activation in cystic fibrosis
    Ciabattoni, G
    Davì, C
    Collura, M
    Iapichino, L
    Pardo, F
    Ganci, A
    Romagnoli, R
    Maclouf, J
    Patrono, C
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (04) : 1195 - 1201
  • [5] Davì G, 1999, CIRCULATION, V99, P224
  • [6] In vivo formation of 8-epi-prostaglandin F-2 alpha is increased in hypercholesterolemia
    Davi, G
    Alessandrini, P
    Mezzetti, A
    Minotti, G
    Bucciarelli, T
    Costantini, F
    Cipollone, F
    Bon, GB
    Ciabattoni, G
    Patrono, C
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 3230 - 3235
  • [7] 8-Epi PGF(2 alpha): Specific analysis of an isoeicosanoid as an index of oxidant stress in vivo
    Delanty, N
    Reilly, M
    Pratico, D
    Fitzgerald, DJ
    Lawson, JA
    FitzGerald, GA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (01) : 15 - 19
  • [8] Mechanisms of disease - Antioxidants and atherosclerotic heart disease
    Diaz, MN
    Frei, B
    Vita, JA
    Keaney, JF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) : 408 - 416
  • [9] Treatment of hypertension with ascorbic acid
    Duffy, SJ
    Gokce, N
    Holbrook, M
    Huang, A
    Frei, B
    Keaney, JF
    Vita, JA
    [J]. LANCET, 1999, 354 (9195) : 2048 - 2049
  • [10] Combination oral antioxidant supplementation reduces blood pressure
    Galley, HF
    Thornton, J
    Howdle, PD
    Walker, BE
    Webster, NR
    [J]. CLINICAL SCIENCE, 1997, 92 (04) : 361 - 365